For UK pharmaceutical and life sciences leaders
Your KOLs are engaged but they are not advocating for you
Relationships with influential clinicians only convert to advocacy when clinicians feel genuine ownership of the evidence. Most UK KOL programmes are structured the wrong way around, and the budget keeps running regardless.
Two minutes. Solva follows up with specific programme restructuring options.
KOL programmes built on scientific partnership generate three times the advocacy output of those built on speaker fees alone.
Frequently asked questions
Why does this problem persist?
KOL engagement in the UK is often done backwards. Companies identify influential clinicians and then ask them to advocate for a product. Clinicians who feel they are being used as a commercial tool disengage.
What is the cost of leaving it unaddressed?
A KOL programme that isn't generating advocacy is a budget line with no commercial return.
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.